Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With CYT Stock Today?
Cyteir Therapeutics Inc (CYT) stock is down -2.38% while the S&P 500 is higher by 0.54% as of 12:09 PM on Thursday, Jan 26. CYT is lower by -$0.04 from the previous closing price of $1.68 on volume of 14,513 shares. Over the past year the S&P 500 is lower by -7.31% while CYT is lower by -74.33%. CYT earned -$1.39 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 42.35.
More About Cyteir Therapeutics Inc
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing the next generation of precision oncology medicines that inhibit DNA damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Its lead program is CYT-0851, which is designed to exploit a novel synthetic lethality between overexpression of a family of DNA damaging enzymes called cytidine deaminases and functional inhibition of homologous recombination, a DNA repair pathway critical for the survival of some cancers. Its Pre-clinical program is CYT-1853, which is designed to exploit the same novel synthetic lethality targeted by CYT-085.
Click Here to get the full Stock Report for Cyteir Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
